← Pharmacy curriculum
Module 21112 lessonsRxPrep 2023 depression chapter on printed pages 834 to 844, reconciled with the 2022 VA/DoD MDD guideline and current FDA labeling for SPRAVATO, ZURZUVAE, VRAYLAR, and CAPLYTA. Goodnotes lecture reconciliation remains pending until the desktop library is unlocked.

Major Depressive Disorder

Diagnose major depressive disorder, protect safety, select and monitor individualized treatment, recognize toxicity, and build a measured pathway from acute response to durable recovery.

01

Apply DSM-5-TR episode criteria and exclusions.

02

Screen for bipolarity and secondary causes.

03

Build an urgent suicide-safety pathway.

04

Use measurement-based follow-up.

05

Match psychotherapy and medication to patient goals.

06

Compare antidepressant pharmacology and selection.

07

Prevent interaction and discontinuation harm.

08

Plan perinatal and postpartum care without obsolete pregnancy letters.

09

Confirm an adequate trial before declaring resistance.

10

Choose switching, augmentation, esketamine, TMS, or ECT appropriately.

11

Monitor treatment-specific safety.

12

Design continuation, maintenance, and relapse-prevention care.

211.01

Diagnose the Episode, Not One Symptom

MDD is a syndromic and functional diagnosis. It requires a complete episode history, exclusions, and a search for bipolar, medical, substance, medication, and contextual explanations.

What to learn
  • DSM-5-TR
  • Anhedonia
  • Impairment
  • Bipolar screen
  • Differential
Clinical reasoning

diagnosis differential

Connect diagnosis, safety, treatment fit, and measured recovery.

Build the episode

Confirm at least five symptoms in the same two-week period, including depressed mood or diminished interest or pleasure. Establish change from baseline, distress or impairment, and the absence of a better explanation.

Test the differential

Ask about past mania or hypomania, psychosis, anxiety, trauma, grief, sleep, substances, medications, pain, pregnancy, thyroid disease, neurologic disease, and other relevant medical conditions.

Describe severity precisely

Symptoms, function, psychosis, catatonia, nutrition, self-care, suicide risk, recurrence, and chronicity matter more than a single adjective or score.

Avoid chemical-imbalance shorthand

Monoamine, glutamate, stress, inflammatory, circadian, network, genetic, and environmental models inform treatment, but no routine test proves a simple neurotransmitter deficiency.

0 of 1 answered
01What must be assessed before antidepressant monotherapy?
Answer every question to submit.
211.02

Make Safety a Clinical Pathway

Suicide screening is an opening, not a disposition. Current thoughts, intent, plan, access, behavior, intoxication, agitation, supports, and ability to collaborate determine the next action.

What to learn
  • Ideation
  • Intent
  • Plan
  • Means
  • Protective factors
Clinical reasoning

suicide safety

Connect diagnosis, safety, treatment fit, and measured recovery.

Ask directly

Use clear language about passive death wishes, active thoughts, intent, plan, preparation, past attempts, interrupted attempts, self-injury, and access to lethal means.

Recognize immediacy

A specific plan, intent, available means, severe agitation, intoxication, psychosis, recent attempt, or inability to maintain safety can require emergency intervention and continuous supervision.

Build a collaborative safety plan

Identify warning signs, internal coping, people and places for distraction, support contacts, professional resources, lethal-means reduction, and the next scheduled contact.

Escalate treatment without false reassurance

Antidepressants do not provide immediate protection. Urgent psychotherapy, crisis care, hospitalization, ECT, or other rapid interventions may be necessary.

0 of 1 answered
01A patient has intent, a firearm, and a near-term plan. What is the priority?
Answer every question to submit.
211.03

Measure What Recovery Changes

A validated symptom scale becomes useful only when paired with function, safety, adherence, adverse effects, goals, and a planned response to the result.

What to learn
  • PHQ-9
  • Function
  • Psychotherapy
  • Shared choice
  • Follow-up
Clinical reasoning

measurement psychotherapy

Connect diagnosis, safety, treatment fit, and measured recovery.

Create a baseline

Record symptoms, function, sleep, appetite, cognition, pain, substance use, adherence barriers, adverse-effect priorities, and patient-defined recovery goals.

Select psychotherapy

CBT, behavioral activation, interpersonal therapy, problem-solving therapy, and other evidence-based approaches can be first-line or combined with medication.

Match intensity to need

Mild illness may begin with psychotherapy or medication. More severe, recurrent, psychotic, catatonic, or dangerous illness needs more intensive and often combined care.

Close the loop

Set the next review date, target change, adherence check, safety check, and explicit action if the target is not met.

0 of 1 answered
01What makes measurement-based care actionable?
Answer every question to submit.
211.04

Use SSRI Differences Deliberately

SSRIs share serotonin-transporter inhibition, but half-life, interactions, QT effect, activation, sedation, withdrawal, dosage forms, and patient experience differ.

What to learn
  • SERT
  • Sexual effects
  • Hyponatremia
  • Bleeding
  • QT
Clinical reasoning

ssri selection

Connect diagnosis, safety, treatment fit, and measured recovery.

Explain the mechanism and timeline

SERT inhibition increases synaptic serotonin quickly, while clinical response emerges through downstream adaptation over weeks. Early adverse effects can precede benefit.

Anticipate class effects

Discuss nausea, diarrhea, headache, sleep change, activation, sweating, sexual dysfunction, bruising or bleeding, hyponatremia, and discontinuation symptoms.

Use individual differences

Fluoxetine has a long half-life and important CYP2D6 inhibition. Paroxetine has anticholinergic, weight, sexual, withdrawal, and pregnancy-selection concerns. Citalopram requires QT-aware dosing.

Monitor the transition

Review adherence, activation, suicidality, serotonin toxicity, sodium risk, bleeding exposures, and early symptom trajectory after initiation or dose change.

0 of 1 answered
01Which feature makes fluoxetine discontinuation symptoms less abrupt than paroxetine?
Answer every question to submit.
211.05

Add Norepinephrine With a Monitoring Plan

SNRIs can be useful when depression coexists with selected pain syndromes, but blood pressure, pulse, activation, nausea, and withdrawal shape fit.

What to learn
  • SERT
  • NET
  • Pain
  • Blood pressure
  • Withdrawal
Clinical reasoning

snri selection

Connect diagnosis, safety, treatment fit, and measured recovery.

Connect dose and pharmacology

Serotonin effects often dominate at lower doses for some agents, with more norepinephrine contribution as exposure rises. This pattern is not identical across the class.

Use pain indications precisely

Duloxetine can serve selected neuropathic pain, fibromyalgia, and musculoskeletal indications. Venlafaxine and desvenlafaxine should not inherit every duloxetine indication.

Respect organ function

Renal and hepatic function can change dosing or suitability. Duloxetine deserves special caution with substantial liver disease or heavy alcohol exposure.

Plan discontinuation

Shorter half-life agents can cause rapid withdrawal. Use a patient-specific taper and distinguish withdrawal from relapse.

0 of 1 answered
01What should be checked routinely with an SNRI that can raise pressure?
Answer every question to submit.
211.06

Select by the Patient's Burden

Bupropion, mirtazapine, vortioxetine, vilazodone, and trazodone offer different tradeoffs in sleep, appetite, weight, sexual function, activation, interactions, and dosage instructions.

What to learn
  • Bupropion
  • Mirtazapine
  • Vortioxetine
  • Vilazodone
  • Trazodone
Clinical reasoning

other antidepressants

Connect diagnosis, safety, treatment fit, and measured recovery.

Use bupropion safely

Its norepinephrine and dopamine reuptake effects can support energy and reduce sexual burden, but seizure disorders, eating disorders, and abrupt sedative or alcohol withdrawal are major contraindication contexts.

Use mirtazapine intentionally

Sedation, appetite stimulation, and weight gain may help or harm depending on insomnia, frailty, nausea, appetite, obesity, and patient goals.

Respect administration details

Vilazodone is taken with food. Vortioxetine has CYP2D6 considerations. Every agent still needs serotonergic and interaction review.

Treat trazodone as a real drug

Sedation, orthostasis, falls, and priapism require counseling. Low-dose insomnia use is not equivalent to a full antidepressant trial.

0 of 1 answered
01Which patient factor strongly argues against bupropion?
Answer every question to submit.
211.07

Reserve High-Burden Tools for the Right Case

TCAs and MAOIs can be effective but require more expertise because receptor promiscuity, overdose toxicity, conduction effects, interactions, and dietary restrictions narrow their margin.

What to learn
  • Anticholinergic
  • Sodium channels
  • Tyramine
  • Washout
  • Overdose
Clinical reasoning

tca maoi

Connect diagnosis, safety, treatment fit, and measured recovery.

Map TCA effects

Monoamine reuptake inhibition accompanies muscarinic, histamine, alpha-1, and cardiac sodium-channel effects. Dry mouth, constipation, urinary retention, sedation, orthostasis, and conduction toxicity follow from that map.

Protect against overdose harm

Assess suicide risk, cardiac disease, falls, cognition, glaucoma, urinary retention, and anticholinergic burden before prescribing. Limit quantities when appropriate.

Control MAOI interactions

Irreversible nonselective MAO inhibition creates risk with serotonergic drugs, sympathomimetics, and high-tyramine foods. Patients need a written interaction plan.

Calculate washout

Most serotonergic drugs require adequate washout before an MAOI. Fluoxetine requires a longer interval because fluoxetine and norfluoxetine persist.

0 of 1 answered
01Why is a large TCA supply risky in a suicidal patient?
Answer every question to submit.
211.08

Separate Toxicity, Withdrawal, and Relapse

Serotonin toxicity and antidepressant discontinuation are mechanistically different emergencies and syndromes, while relapse follows a different timing and symptom pattern.

What to learn
  • Clonus
  • Hyperreflexia
  • FINISH
  • Timing
  • Taper
Clinical reasoning

toxicity discontinuation

Connect diagnosis, safety, treatment fit, and measured recovery.

Recognize serotonin toxicity

Recent serotonergic exposure plus clonus, hyperreflexia, tremor, agitation, diaphoresis, diarrhea, autonomic instability, or hyperthermia should trigger urgent evaluation.

Treat severe toxicity

Stop serotonergic agents, provide supportive care, use benzodiazepines for agitation when appropriate, and aggressively manage severe hyperthermia and complications.

Recognize discontinuation

Flu-like symptoms, insomnia, nausea, imbalance, sensory symptoms, and hyperarousal can begin soon after reduction of a shorter half-life agent.

Design the taper

Reduce gradually, slow further if symptoms emerge, and individualize to dose, duration, half-life, prior withdrawal, relapse risk, and patient preference.

0 of 1 answered
01Which finding most supports serotonin toxicity?
Answer every question to submit.
211.09

Treat the Illness and the Reproductive Context

Perinatal decisions compare the harms of untreated or relapsing illness with treatment evidence, pregnancy timing, lactation, maternal function, infant care, and patient values.

What to learn
  • Pregnancy
  • Lactation
  • Relapse
  • Zuranolone
  • Support
Clinical reasoning

perinatal postpartum

Connect diagnosis, safety, treatment fit, and measured recovery.

Do not stop automatically

A patient with severe, recurrent, psychotic, or suicidal depression may face substantial relapse risk from abrupt discontinuation. Review prior course and alternatives before changing an effective regimen.

Plan medication and psychotherapy together

Use the best-supported effective option at the lowest complexity that maintains wellness, while considering reproductive safety evidence, neonatal adaptation, and lactation.

Recognize postpartum urgency

Assess suicidality, psychosis, mania, ability to sleep, infant safety, supports, and medical causes. Postpartum psychosis is an emergency and is not simply severe MDD.

Use neuroactive steroids accurately

Oral zuranolone is a 14-day course for adults with postpartum depression and carries prominent sedation and driving-impairment counseling. Brexanolone requires a supervised continuous infusion under its program and label.

0 of 1 answered
01What is essential when prescribing zuranolone?
Answer every question to submit.
211.10

Prove the Trial Before Calling It Resistant

Apparent treatment resistance may reflect the wrong diagnosis, inadequate dose or duration, nonadherence, intolerance, substance use, medical illness, unresolved trauma, or inaccessible psychotherapy.

What to learn
  • Adequacy
  • Adherence
  • Pseudo-resistance
  • Switch
  • Augment
Clinical reasoning

inadequate response

Connect diagnosis, safety, treatment fit, and measured recovery.

Audit the diagnosis

Reassess bipolarity, psychosis, substance use, ADHD, trauma, personality, grief, sleep apnea, pain, thyroid disease, anemia, and medication contributors as indicated.

Audit the trial

Document drug, formulation, dose, duration, adherence, exposure-changing interactions, response, adverse effects, reason stopped, and whether psychotherapy was available.

Choose switch or augmentation

Switch when tolerability is poor or response is minimal. Consider augmentation when a well-tolerated treatment produced meaningful partial response.

Set a stop rule

Every adjunct needs a target, baseline, follow-up interval, safety monitoring, and a plan to stop if benefit does not justify burden.

0 of 1 answered
01What should happen before labeling TRD?
Answer every question to submit.
211.11

Escalate With Precision

Augmentation, esketamine, TMS, and ECT are distinct interventions with different indications, speed, logistics, monitoring, and evidence.

What to learn
  • Lithium
  • Atypical antipsychotic
  • Esketamine
  • TMS
  • ECT
Clinical reasoning

advanced treatment

Connect diagnosis, safety, treatment fit, and measured recovery.

Use augmentation intentionally

Selected antipsychotics have adjunctive MDD indications, including aripiprazole, brexpiprazole, quetiapine XR, cariprazine, and, under current 2025 labeling, lumateperone. Verify current label, dose, interactions, metabolic and movement risks.

Use esketamine under the REMS

SPRAVATO is administered under supervision with post-dose monitoring. Current labeling permits monotherapy or combination with an oral antidepressant for adult TRD, while acute suicidal ideation or behavior treatment is paired with an oral antidepressant.

Place TMS appropriately

TMS is noninvasive and avoids systemic drug exposure but requires repeated visits and device-specific protocols. It is not a substitute for emergency containment of imminent risk.

Use ECT when speed and efficacy matter

Severe psychotic depression, catatonia, profound nutritional compromise, urgent suicidality, pregnancy in selected cases, and prior strong response can justify early ECT consultation.

0 of 1 answered
01Can current SPRAVATO labeling support adult TRD monotherapy?
Answer every question to submit.
211.12

Turn Response Into Durable Recovery

Initial symptom improvement is not the endpoint. Remission, function, safety, relationships, cognition, sleep, work, adherence, and the patient's own goals define recovery.

What to learn
  • Response
  • Remission
  • Continuation
  • Maintenance
  • Relapse prevention
Clinical reasoning

recovery plan

Connect diagnosis, safety, treatment fit, and measured recovery.

Differentiate phases

Acute treatment seeks response and remission. Continuation consolidates remission. Maintenance prevents recurrence in patients with greater long-term risk.

Individualize duration

Recurrent episodes, chronic depression, severe episodes, psychosis, suicidality, residual symptoms, comorbidity, and prior relapse after stopping support longer maintenance.

Preserve what worked

Document effective dose, psychotherapy skills, sleep and activity routines, social supports, adverse effects, barriers, and the earliest personal warning signs.

Coordinate ownership

Name who monitors symptoms, safety, medications, metabolic or organ-specific risks, psychotherapy, reproductive needs, and the next escalation decision.

0 of 1 answered
01What should happen after remission?
Answer every question to submit.

Check the connections.

Each attempt draws 10 questions from the complete 100 question bank.

100 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. VA/DoD Clinical Practice Guideline for Management of Major Depressive Disorder, 2022
  2. FDA SPRAVATO Prescribing Information, 2025
  3. FDA ZURZUVAE Prescribing Information
  4. FDA VRAYLAR Prescribing Information
  5. FDA CAPLYTA Prescribing Information, 2025
PharmacyOpen tools